留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝移植术后新发恶性肿瘤危险因素的研究进展

孟令展 刘振文 朱震宇

孟令展, 刘振文, 朱震宇. 肝移植术后新发恶性肿瘤危险因素的研究进展[J]. 器官移植, 2020, 11(5): 646-650. doi: 10.3969/j.issn.1674-7445.2020.05.019
引用本文: 孟令展, 刘振文, 朱震宇. 肝移植术后新发恶性肿瘤危险因素的研究进展[J]. 器官移植, 2020, 11(5): 646-650. doi: 10.3969/j.issn.1674-7445.2020.05.019
Meng Lingzhan, Liu Zhenwen, Zhu Zhenyu. Research progress on risk factors of de novo malignancy after liver transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(5): 646-650. doi: 10.3969/j.issn.1674-7445.2020.05.019
Citation: Meng Lingzhan, Liu Zhenwen, Zhu Zhenyu. Research progress on risk factors of de novo malignancy after liver transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(5): 646-650. doi: 10.3969/j.issn.1674-7445.2020.05.019

肝移植术后新发恶性肿瘤危险因素的研究进展

doi: 10.3969/j.issn.1674-7445.2020.05.019
基金项目: 国家自然科学基金(81572462)
详细信息
    作者简介:

    孟令展,男,1985年生,硕士研究生,主治医师,研究方向为肝移植,Email:mlzno1@163.com

    通讯作者:

    朱震宇,男,1979年生,博士,副主任医师,研究方向为肝移植与肝脏肿瘤,Email:zhuzy302@163.com

  • 中图分类号: R617, R73

Research progress on risk factors of de novo malignancy after liver transplantation

More Information
    Corresponding author: Zhu Zhenyu, Email: zhuzy302@163.com
  • 摘要: 肝移植术后新发恶性肿瘤是影响受者远期生存率的重要因素,其主要的危险因素包括免疫抑制以及诸多受者因素,如年龄、性别、种族、原发病、术前肿瘤病史及癌前病变、致癌病毒感染以及吸烟和饮酒等。肝移植术后新发恶性肿瘤目前尚无标准化的监测方案,但对于高危受者,需要有计划地监测,以期能够早期诊断,提高其生存率。本文就肝移植术后新发恶性肿瘤发生率、预后及相关危险因素等进行综述,为提高肝移植术后受者远期生存率提供参考。

     

  • [1] CHATRATH H, BERMAN K, VUPPALANCHI R, et al. De novo malignancy post-liver transplantation: a single center, population controlled study[J]. Clin Transplant, 2013, 27(4):582-590. DOI: 10.1111/ctr.12171.
    [2] ZHOU J, HU Z, ZHANG Q, et al. Spectrum of de novo cancers and predictors in liver transplantation: analysis of the scientific registry of transplant recipients database[J]. PLoS One, 2016, 11(5):e0155179. DOI:10.1371/journal. pone.0155179.
    [3] PARK HW, HWANG S, AHN CS, et al. De novo malignancies after liver transplantation: incidence comparison with the Korean cancer registry[J]. Transplant Proc, 2012, 44(3):802- 805. DOI: 10.1016/j.transproceed.2012.01.027.
    [4] AGUIAR D, MARTÍNEZ-URBISTONDO D, D'AVOLA D, et al. Conversion from calcineurin inhibitor-based immunosuppression to mycophenolate mofetil in monotherapy reduces risk of de novo malignancies after liver transplantation[J]. Ann Transplant, 2017, 22:141- 147. DOI: 10.12659/aot.901556.
    [5] RADEMACHER S, SEEHOFER D, EURICH D, et al. The 28-year incidence of de novo malignancies after liver transplantation: a single-center analysis of risk factors and mortality in 1616 patients[J]. Liver Transpl, 2017, 23(11):1404-1414. DOI: 10.1002/lt.24795.
    [6] NORDIN A, ÅBERG F, PUKKALA E, et al. Decreasing incidence of cancer after liver transplantation-a Nordic population-based study over 3 decades[J]. Am J Transplant, 2018, 18(4):952-963. DOI: 10.1111/ajt.14507.
    [7] BHAT M, MARA K, DIERKHISING R, et al. Gender, race and disease etiology predict de novo malignancy risk after liver transplantation: insights for future individualized cancer screening guidance[J]. Transplantation, 2019, 103(1): 91-100. DOI: 10.1097/TP.0000000000002113.
    [8] SHERSTON SN, CARROLL RP, HARDEN PN, et al. Predictors of cancer risk in the long-term solid-organ transplant recipient[J]. Transplantation, 2014, 97(6):605- 611. DOI: 10.1097/01.TP.0000436907.56425.5c.
    [9] JIMÉNEZ-ROMERO C, JUSTO-ALONSO I, CAMBRAMOLERO F, et al. Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosis[J]. World J Hepatol, 2015, 7(7):942- 953. DOI: 10.4254/wjh.v7.i7.942.
    [10] TJON AS, SINT NICOLAAS J, KWEKKEBOOM J, et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age[J]. Liver Transpl, 2010, 16(7):837-846. DOI: 10.1002/lt.22064.
    [11] WIMMER CD, ANGELE MK, SCHWARZ B, et al. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients[J]. Transpl Int, 2013, 26(10):999-1006. DOI: 10.1111/tri.12165.
    [12] CARENCO C, ASSENAT E, FAURE S, et al. Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship[J]. Am J Transplant, 2015, 15(3):678- 686. DOI: 10.1111/ajt.13018.
    [13] RODRÍGUEZ-PERÁLVAREZ M, GERMANI G, DARIUS T, et al. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and Meta-analysis[J]. Am J Transplant, 2012, 12(10):2797-2814. DOI: 10.1111/j.1600-6143.2012.04140.x.
    [14] CHOLONGITAS E, MAMOU C, RODRÍGUEZ-CASTRO KI, et al. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review[J]. Transpl Int, 2014, 27(10):1039-1049. DOI: 10.1111/tri.12372.
    [15] THIMONIER E, GUILLAUD O, WALTER T, et al. Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease[J]. Clin Transplant, 2014, 28(12): 1339-1348. DOI: 10.1111/ctr.12430.
    [16] HERRERO JI, LUCENA JF, QUIROGA J, et al. Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy[J]. Am J Transplant, 2003, 3(11):1407-1412. DOI:10.1046/j.1600- 6143.2003.00227.x.
    [17] SÉRÉE O, ALTIERI M, GUILLAUME E, et al. Longterm risk of solid organ de novo malignancies after liver transplantation: a French national study on 11, 226 patients[J]. Liver Transpl, 2018, 24(10):1425-1436. DOI: 10.1002/lt.25310.
    [18] TANAKA T, VOIGT MD. Decision tree analysis to stratify risk of de novo non-melanoma skin cancer following liver transplantation[J]. J Cancer Res Clin Oncol, 2018, 144(3):607-615. DOI:10.1007/s00432-018- 2589-5.
    [19] 姜晓青, 张群, 解曼, 等.中国肝移植术后新发消化系统恶性肿瘤文献分析报告[J].器官移植, 2020, 11(2): 265-270. DOI: 10.3969/j.issn.1674-7445.2020.02.013.

    JIANG XQ, ZHANG Q, XIE M, et al. Literature analysis report of de novo malignant tumors of digestive system after liver transplantation in China[J]. Organ Transplant, 2020, 11(2): 265-270. DOI: 10.3969/j.issn.1674-7445. 2020.02.013.
    [20] WATT KD, PEDERSEN RA, KREMERS WK, et al. Long-term probability of and mortality from de novo malignancy after liver transplantation[J]. Gastroenterology, 2009, 137(6):2010-2017. DOI: 10.1053/j.gastro.2009.08.070.
    [21] SANNA C, ROSSO C, MARIETTI M, et al. Non-alcoholic fatty liver disease and extra-hepatic cancers[J]. Int J Mol Sci, 2016, 17(5):717. DOI: 10.3390/ijms17050717.
    [22] PARK GC, HWANG S, AHN CS, et al. Pretransplant hepatic malignancy increases risk of de novo malignancy after liver transplantation[J]. J Korean Med Sci, 2020, 35(11):e69. DOI: 10.3346/jkms.2020.35.e69.
    [23] MENACHEM Y, SAFADI R, ASHUR Y, et al. Malignancy after liver transplantation in patients with premalignant conditions[J]. J Clin Gastroenterol, 2003, 36(5):436-439. DOI: 10.1097/00004836-200305000-00016.
    [24] OEZCELIK A, KAISER GM, DECHÊNE A, et al. Progression to adenocarcinoma in Barrett's esophagus after liver transplantation[J]. Transplantation, 2011, 91(11):1250- 1253. DOI: 10.1097/TP.0b013e31821841a0.
    [25] PISELLI P, BUSNACH G, FRATINO L, et al. De novo malignancies after organ transplantation: focus on viral infections[J]. Curr Mol Med, 2013, 13(7):1217-1227. DOI: 10.2174/15665240113139990041.
    [26] TABORELLI M, PISELLI P, ETTORRE GM, et al. Risk of virus and non-virus related malignancies following immunosuppression in a cohort of liver transplant recipients. Italy, 1985-2014[J]. Int J Cancer, 2018, 143(7):1588-1594. DOI: 10.1002/ijc.31552.
    [27] TREVISANI F, GARUTI F, CUCCHETTI A, et al. De novo hepatocellular carcinoma of liver allograft: a neglected issue[J]. Cancer Lett, 2015, 357(1):47-54. DOI: 10.1016/j.canlet.2014.11.032.
    [28] MANGUS RS, FRIDELL JA, KUBAL CA, et al. Worse long-term patient survival and higher cancer rates in liver transplant recipients with a history of smoking[J]. Transplantation, 2015, 99(9):1862-1868. DOI:10.1097/ TP.0000000000000671.
    [29] HERRERO JI, PARDO F, D'AVOLA D, et al. Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal[J]. Liver Transpl, 2011, 17(4):402-408. DOI: 10.1002/lt.22247.
    [30] BHAT M, MARA K, DIERKHISING R, et al. Immunosuppression, race, and donor-related risk factors affect de novo cancer incidence across solid organ transplant recipients[J]. Mayo Clin Proc, 2018, 93(9):1236- 1246. DOI: 10.1016/j.mayocp.2018.04.025.
  • 加载中
计量
  • 文章访问数:  163
  • HTML全文浏览量:  65
  • PDF下载量:  27
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-06-10
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2020-09-15

目录

    /

    返回文章
    返回